Evaluation of COX-1/COX-2 selectivity and potency of a new class of COX-2 inhibitors

被引:28
作者
Gierse, James [1 ]
Nickols, Maureen [1 ]
Leahy, Kathleen [1 ]
Warner, James [1 ]
Zhang, Yan [2 ]
Cortes-Burgos, Luz [1 ]
Carter, Jeffery [1 ]
Seibert, Karen [1 ]
Masferrer, Jaime [1 ]
机构
[1] Pfizer Global Res & Dev, Chesterfield, MO 63198 USA
[2] Kalypsys Inc, San Diego, CA 92121 USA
关键词
COX-2; cyclooxygenase; inhibitor; selectivity;
D O I
10.1016/j.ejphar.2008.03.057
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A new class of selective cyclooxygenase-2 (COX-2) inhibitors has been identified by high throughput screening. Structurally distinct from previously described selective COX-2 inhibitors, these benzopyrans contain a carboxylic acid function and CF3 functionality. The compound SC-75416 is a representative of this class. A range if in vitro and in vivo tests were employed to characterize its potency and selectivity. Using human recombinant enzymes, this compound displays a concentration that provides 50% inhibition (IC50) of 0.25 mu M for COX-2 and 49.6 mu M for COX-1. A mutation of the side pocket residues in COX-2 to COX-1 had little effect on potency suggesting that these inhibitors bind in a unique manner in COX-2 distinct from COX-2 inhibiting diaryl heterocycles. Using rheumatoid arthritic synovial cells stimulated with interleukin-1 beta (IL-1 beta) and washed platelets the compound displayed IC50 of 3 nM and 400 nM respectively. Potency and selectivity was maintained but predictably right shifted in whole blood with IC50 of 1.4 mu M for lipopolysaccharide (LPS) stimulated induction of COX-2 and > 200 mu M for inhibition of platelet thromboxane production. SC-75416 is 89% bioavailable and its in vivo half life is sufficient for once a day dosing. In the rat air pouch model of inflammation, the compound inhibited PGF(2) production with an effective dose that provides 50% inhibition (ED50) of 0.4 mg/kg, while sparing gastric prostaglandin E2 (PGE(2)) production with an ED50 of 26.5 mg/kg. in a model of acute inflammation and pain caused by carrageenan injection into the rat paw, the compound reduced edema and hyperalgesia with ED(50)s of 2.7 and 4 mg/kg respectively. in a chronic model of arthritis the compound demonstrated an ED50 of 0.081 mg/kg and an ED80 of 0.38 mg/kg. In a model of neuropathic pain, SC-75416 had good efficacy. This compound's unique chemical structure and effect on COX enzyme binding and activity as well as its potency and selectivity may prove useful in treating pain and inflammation. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:93 / 98
页数:6
相关论文
共 26 条
[1]   The cyclooxygenase-2 inhibitor GW406381X [2-(4-ethoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-pyrazolo[ 1,5-b]pyridazine] is effective in animal models of neuropathic pain and central sensitization [J].
Bingham, S ;
Beswick, PJ ;
Bountra, C ;
Brown, T ;
Campbell, IB ;
Chessell, IP ;
Clayton, N ;
Collins, SD ;
Davey, PT ;
Goodland, H ;
Gray, N ;
Haslam, C ;
Hatcher, JP ;
Hunter, AJ ;
Lucas, F ;
Murkitt, G ;
Naylor, A ;
Pickup, E ;
Sargent, B ;
Summerfield, SG ;
Stevens, A ;
Stratton, SC ;
Wiseman, J .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 312 (03) :1161-1169
[2]   2,3-diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors [J].
Black, WC ;
Brideau, C ;
Chan, CC ;
Charleson, S ;
Chauret, N ;
Claveau, D ;
Ethier, D ;
Gordon, R ;
Greig, G ;
Guay, J ;
Hughes, G ;
Jolicoeur, P ;
Leblanc, Y ;
Nicoll-Griffith, D ;
Ouimet, N ;
Riendeau, D ;
Visco, D ;
Wang, ZY ;
Xu, L ;
Prasit, P .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (07) :1274-1281
[3]   MECHANISM OF SELECTIVE-INHIBITION OF THE INDUCIBLE ISOFORM OF PROSTAGLANDIN G/H SYNTHASE [J].
COPELAND, RA ;
WILLIAMS, JM ;
GIANNARAS, J ;
NURNBERG, S ;
COVINGTON, M ;
PINTO, D ;
PICK, S ;
TRZASKOS, JM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (23) :11202-11206
[4]  
Crofford LJ, 1997, J RHEUMATOL, V24, P15
[5]   Valdecoxib: Assessment of cyclooxygenase-2 potency and selectivity [J].
Gierse, JK ;
Zhang, Y ;
Hood, WF ;
Walker, MC ;
Trigg, JS ;
Maziasz, TJ ;
Koboldt, CM ;
Muhammad, JL ;
Zweifel, BS ;
Masferrer, JL ;
Isakson, PC ;
Seibert, K .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 312 (03) :1206-1212
[6]   Kinetic basis for selective inhibition of cyclo-oxygenases [J].
Gierse, JK ;
Koboldt, CM ;
Walker, MC ;
Seibert, K ;
Isakson, PC .
BIOCHEMICAL JOURNAL, 1999, 339 :607-614
[7]   EXPRESSION AND SELECTIVE-INHIBITION OF THE CONSTITUTIVE AND INDUCIBLE FORMS OF HUMAN CYCLOOXYGENASE [J].
GIERSE, JK ;
HAUSER, SD ;
CREELY, DP ;
KOBOLDT, C ;
RANGWALA, SH ;
ISAKSON, PC ;
SEIBERT, K .
BIOCHEMICAL JOURNAL, 1995, 305 :479-484
[8]   A NEW AND SENSITIVE METHOD FOR MEASURING THERMAL NOCICEPTION IN CUTANEOUS HYPERALGESIA [J].
HARGREAVES, K ;
DUBNER, R ;
BROWN, F ;
FLORES, C ;
JORIS, J .
PAIN, 1988, 32 (01) :77-88
[9]   A selective IKK-2 inhibitor blocks NF-κB-dependent gene expression in interleukin-1β-stimulated synovial fibroblasts [J].
Kishore, N ;
Sommers, C ;
Mathialagan, S ;
Guzova, J ;
Yao, M ;
Hauser, S ;
Huynh, K ;
Bonar, S ;
Mielke, C ;
Albee, L ;
Weier, R ;
Graneto, M ;
Hanau, C ;
Perry, T ;
Tripp, CS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (35) :32861-32871
[10]  
KOWALSKI KG, 2007, CLIN PHARM THER